Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
PLoS One. 2013 May 10;8(5):e63706. doi: 10.1371/journal.pone.0063706. Print 2013.
Nasopharyngeal Carcinoma (NPC) is a major health problem in southern and eastern Asia. In Indonesia NPC is the most frequent cancer in the head and neck area. NPC is very sensitive to radiotherapy resulting in 3-year disease-free and overall survival of approximately 70% and 80%, respectively. Here we present routine treatment results in a prospective study on NPC in a top referral; university hospital in Indonesia.
All NPC patients presenting from September 2008 till January 2011 at the ear, nose and throat (ENT) department of the Dr. Sardjito General Hospital, Universitas Gadjah Mada, Yogyakarta, Indonesia, were possible candidates. Patients were included if the biopsy was a histological proven NPC without distant metastasis and were assessed during counselling sessions prior to treatment, as being able to complete the entire treatment.
In total 78 patients were included for treatment analysis. The median time between diagnosis and start of radiotherapy is 120 days. Forty-eight (62%) patients eventually finished all fractions of radiotherapy. The median duration of the radiotherapy is 62 days for 66 Gy. Median overall survival is 21 months (95% CI 18-35) from day of diagnosis.
The results presented here reveal that currently the treatment of NPC at an Indonesian hospital is not sufficient and cannot be compared to the treatment results in literature. Main reasons for these poor treatment results are (1) a long waiting time prior to the start of radiotherapy, (2) the extended overall duration of radiotherapy and (3) the advanced stage of disease at presentation.
鼻咽癌(NPC)是南亚和东亚地区的一个主要健康问题。在印度尼西亚,NPC 是头颈部最常见的癌症。NPC 对放疗非常敏感,3 年无病生存率和总生存率分别约为 70%和 80%。在此,我们介绍了在印度尼西亚一家顶级转诊大学医院进行的 NPC 前瞻性研究中的常规治疗结果。
所有于 2008 年 9 月至 2011 年 1 月期间在印度尼西亚日惹玛达大学萨迪吉托综合医院耳鼻喉科就诊的 NPC 患者均为可能的候选人。如果活检证实为 NPC 且无远处转移,且在治疗前的咨询期间评估为能够完成整个治疗过程,则患者可被纳入。
共有 78 例患者被纳入治疗分析。从诊断到开始放疗的中位时间为 120 天。最终有 48 例(62%)患者完成了所有放疗剂量。66Gy 的中位放疗持续时间为 62 天。从诊断之日起,中位总生存期为 21 个月(95%CI 18-35)。
目前印度尼西亚医院治疗 NPC 的结果不理想,无法与文献中的治疗结果相媲美。造成这些较差治疗结果的主要原因是:(1)放疗前等待时间长,(2)放疗总持续时间延长,(3)就诊时疾病已处于晚期。